Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.60 |
| ▸ | ESRRB | O95718 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9077833 | 0.89 | HSD17B3 (0.66) | HSD17B3ESRRBNPC1RAB9AALDH1A1 | |
| SCHEMBL8535748 | 0.85 | KMT2A (0.63) | NPC1RAB9AALDH1A1POLBTDP1 | |
| SCHEMBL434768 | 0.84 | CA12 (0.57) | HSD17B3ESRRBNPC1RAB9AALDH1A1 | |
| SCHEMBL7939950 | 0.83 | NPC1 (0.81) | HSD17B3NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL31435094 | 0.83 | ALDH1A1 (0.54) | HSD17B3ESRRBNPC1RAB9AALDH1A1 | |
| SCHEMBL26931597 | 0.83 | ALDH1A1 (0.54) | HSD17B3ESRRBNPC1RAB9AALDH1A1 | |
| SCHEMBL1108994 | 0.83 | MMP1 (0.70) | NPC1RAB9AALDH1A1APEX1RECQL | |
| SCHEMBL9263357 | 0.83 | KMT2A (0.60) | NPC1RAB9AALDH1A1L3MBTL1POLB | |
| SCHEMBL10638823 | 0.83 | KMT2A (0.48) | ESRRBALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL640759 | 0.83 | LMNA (0.60) | NPC1RAB9AALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931266-B1 | COMPOSITION AND KIT COMPRISING PIPERAZINE DERIVATIVES AND METFORMIN, AND USE THEREOF IN THE TREATMENT OF DIABETES | METABOLYS (FR) | 2020-02-05 | — | — | EP | disclosed |
| US-9545387-B2 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | METABOLYS (FR) | 2017-01-17 | — | — | US | disclosed |
| US-9545387-B2 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | METABOLYS (FR) | 2017-01-17 | — | — | US | disclosed |
| US-9545387-B2 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | METABOLYS (FR) | 2017-01-17 | — | — | US | disclosed |
| EP-2723719-B1 | PIPERAZINE DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN THE TREATMENT OF INSULINORESISTANCE | METABOLYS (FR) | 2016-11-30 | — | — | EP | disclosed |
| CN-103796994-B | Piperazine derivatives, preparation method thereof and application thereof in treating insulin resistance | METABOLYS (FR) | 2015-11-25 | — | — | CN | disclosed |
| US-20150297539-A1 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | METABOLYS (FR) | 2015-10-22 | — | — | US | disclosed |
| US-20150297539-A1 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | METABOLYS (FR) | 2015-10-22 | — | — | US | disclosed |
| US-20150297539-A1 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | METABOLYS (FR) | 2015-10-22 | — | — | US | disclosed |
| US-9150529-B2 | Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance | METABOLYS (FR) | 2015-10-06 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-4918092-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1990-04-17 | — | — | US | disclosed |
| US-4761425-A | ANTIASTHMATICS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1988-08-02 | — | — | US | disclosed |
| US-4720505-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1988-01-19 | — | — | US | disclosed |
| EP-0194548-A2 | Sulfonylaminoethyl compounds, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1986-09-17 | — | — | EP | disclosed |
| EP-0147217-A2 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297539-A1 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | KIT, GPR119, INSR | HSD17B3 1830/4885ESRRB 1812/4885NPC1 974/4885 |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | HSD17B3 788/4885ESRRB 78/4885NPC1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.